Anthony W.S. Chan , In Ki Cho , Chun-Xia Li , Xiaodong Zhang , Sudeep Patel , Rebecca Rusnak , Jessica Raper , Jocelyne Bachevalier , Sean P. Moran , Tim Chi , Katherine H. Cannon , Carissa E. Hunter , Ryan C. Martin , Hailian Xiao , Shang-Hsun Yang , Sanjeev Gumber , James G. Herndon , Rebecca F. Rosen , William T. Hu , James J. Lah , Lary C. Walker
{"title":"Cerebral Aβ deposition in an Aβ-precursor protein-transgenic rhesus monkey","authors":"Anthony W.S. Chan , In Ki Cho , Chun-Xia Li , Xiaodong Zhang , Sudeep Patel , Rebecca Rusnak , Jessica Raper , Jocelyne Bachevalier , Sean P. Moran , Tim Chi , Katherine H. Cannon , Carissa E. Hunter , Ryan C. Martin , Hailian Xiao , Shang-Hsun Yang , Sanjeev Gumber , James G. Herndon , Rebecca F. Rosen , William T. Hu , James J. Lah , Lary C. Walker","doi":"10.1016/j.nbas.2022.100044","DOIUrl":null,"url":null,"abstract":"<div><p>With the ultimate goal of developing a more representative animal model of Alzheimer's disease (AD), two female amyloid-β-(Aβ) precursor protein-transgenic (APPtg) rhesus monkeys were generated by lentiviral transduction of the <em>APP</em> gene into rhesus oocytes, followed by <em>in vitro</em> fertilization and embryo transfer. The <em>APP</em>-transgene included the AD-associated Swedish K670N/M671L and Indiana V717F mutations (<em>APPSWE/IND</em>) regulated by the human polyubiquitin-C promoter. Overexpression of <em>APP</em> was confirmed in lymphocytes and brain tissue. Upon sacrifice at 10 years of age, one of the monkeys had developed Aβ plaques and cerebral Aβ-amyloid angiopathy in the occipital, parietal, and caudal temporal neocortices. The induction of Aβ deposition more than a decade prior to its usual emergence in the rhesus monkey supports the feasibility of creating a transgenic nonhuman primate model for mechanistic analyses and preclinical testing of treatments for Alzheimer's disease and cerebrovascular amyloidosis.</p></div>","PeriodicalId":72131,"journal":{"name":"Aging brain","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/92/main.PMC9802652.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging brain","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589958922000160","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 2
Abstract
With the ultimate goal of developing a more representative animal model of Alzheimer's disease (AD), two female amyloid-β-(Aβ) precursor protein-transgenic (APPtg) rhesus monkeys were generated by lentiviral transduction of the APP gene into rhesus oocytes, followed by in vitro fertilization and embryo transfer. The APP-transgene included the AD-associated Swedish K670N/M671L and Indiana V717F mutations (APPSWE/IND) regulated by the human polyubiquitin-C promoter. Overexpression of APP was confirmed in lymphocytes and brain tissue. Upon sacrifice at 10 years of age, one of the monkeys had developed Aβ plaques and cerebral Aβ-amyloid angiopathy in the occipital, parietal, and caudal temporal neocortices. The induction of Aβ deposition more than a decade prior to its usual emergence in the rhesus monkey supports the feasibility of creating a transgenic nonhuman primate model for mechanistic analyses and preclinical testing of treatments for Alzheimer's disease and cerebrovascular amyloidosis.